273 related articles for article (PubMed ID: 9595982)
1. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
[TBL] [Abstract][Full Text] [Related]
2. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
Morrison CE; Borod JC; Brin MF; Hälbig TD; Olanow CW
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1333-41. PubMed ID: 15480842
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
Hanna-Pladdy B; Pahwa R; Lyons KE
J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
[TBL] [Abstract][Full Text] [Related]
4. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
5. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa.
Rampello L; Chiechio S; Raffaele R; Vecchio I; Nicoletti F
Clin Neuropharmacol; 2002; 25(1):21-4. PubMed ID: 11852292
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric symptoms screening in the early stages of Parkinson's disease.
Bugalho P; da Silva JA; Cargaleiro I; Serra M; Neto B
J Neurol; 2012 Jan; 259(1):124-31. PubMed ID: 21691730
[TBL] [Abstract][Full Text] [Related]
7. Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
Gul A; Yousaf J
Singapore Med J; 2019 Aug; 60(8):414-417. PubMed ID: 30246215
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
9. Levodopa medication improves incidental sequence learning in Parkinson's disease.
Beigi M; Wilkinson L; Gobet F; Parton A; Jahanshahi M
Neuropsychologia; 2016 Dec; 93(Pt A):53-60. PubMed ID: 27686948
[TBL] [Abstract][Full Text] [Related]
10. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
Kulisevsky J; García-Sánchez C; Berthier ML; Barbanoj M; Pascual-Sedano B; Gironell A; Estévez-González A
Mov Disord; 2000 Jul; 15(4):613-26. PubMed ID: 10928571
[TBL] [Abstract][Full Text] [Related]
11. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
[TBL] [Abstract][Full Text] [Related]
13. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
14. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Litvinenko IV; Odinak MM; Mogil'naya VI; Perstnev SV
Neurosci Behav Physiol; 2010 Feb; 40(2):149-55. PubMed ID: 20033305
[TBL] [Abstract][Full Text] [Related]
15. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Findings Useful for Driving Safety Advice for Parkinson's Disease Patients.
Ando R; Iwaki H; Tsujii T; Nagai M; Nishikawa N; Yabe H; Aiba I; Hasegawa K; Tsuboi Y; Aoki M; Nakashima K; Nomoto M;
Intern Med; 2018 Jul; 57(14):1977-1982. PubMed ID: 29491315
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Duodopa
Ciurleo R; Corallo F; Bonanno L; Lo Buono V; Di Lorenzo G; Versaci R; Allone C; Palmeri R; Bramanti P; Marino S
J Neurol; 2018 Sep; 265(9):2005-2014. PubMed ID: 29951701
[TBL] [Abstract][Full Text] [Related]
18. Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
Bosco D; Plastino M; Bosco F; Fava A; Rotondo A
Minerva Med; 2011 Apr; 102(2):125-32. PubMed ID: 21483399
[TBL] [Abstract][Full Text] [Related]
19. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
Molloy SA; Rowan EN; O'Brien JT; McKeith IG; Wesnes K; Burn DJ
J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1323-8. PubMed ID: 16952917
[TBL] [Abstract][Full Text] [Related]
20. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
Reddy S; Factor SA; Molho ES; Feustel PJ
Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
